ASH 2017
ASH 2017
-
Next Generation Sequencing ‒ Based Post-Transplant Monitoring in Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantationあとで読む2017年12月14日 17:47
-
Genetic Characterization and Clinical Impact of Loss of MHC Class I and II Expression in De Novo Diffuse Large B-Cell Lymphomaあとで読む2017年12月18日 10:47
-
骨髄異形成症候群に対する脱メチル化薬の効果を予測する遺伝子バイオマーカー
役に立った(1)Genomic biomarkers to predict response to hypomethylating agents in patients with myelodysplastic syndromes (MDS).あとで読む2017年12月18日 10:47
-
Long Term Follow-up of the PRIMA Study: Half of Patients Receiving Rituximab Maintenance Remain Progression Free at 10 Yearsあとで読む2017年12月18日 10:48
-
Comparison of the Efficacy and Feasibility of R-CODOX-M/IVAC-R Versus Conventional R-CHOP As First Line Regimen for Aggressive Diffuse Large B-Cell Lymphomaあとで読む2017年12月18日 10:49
-
Validation of Progression of Disease in 24 months（POD24 ）as a Robust Early Clinical Endpoint of Poor Survival in Follicular Lymphoma: Results from the Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) Investigation Using Individual Data from 5,453 Patients on 13 Clinical Trialsあとで読む2017年12月18日 10:50
-
Randomized Maintenance Therapy with Azacitidine (Vidaza) in Older Patients (≥ 60 years of age) with Acute Myeloid Leukemia (AML) and Refractory Anemia with Excess of Blasts (RAEB, RAEB-t). Results of the HOVON97 Phase III Randomized Multicentre Study (EudraCT 2008-001290-15)あとで読む2017年12月18日 10:52
-
Four versus Two Years of Rituximab Maintenance following Bendamustine-Rituximab in pts with Previously Untreated Follicular Lymphoma:Results of the prospective, randomized multicenter Phase 3 Study (StiL NHL7-2008 MAINTAIN trial)あとで読む2017年12月18日 10:52
-
Discovery and Validation of a Simplified Scoring System (the PRIMA-Prognostic Index) in De Novo Follicular Lymphoma Treated Initially with Immunochemotherapy..あとで読む2017年12月19日 14:44
-
A Comparison of One Year Outcomes in ZUMA-1 (axicabtagene ciloleucel) and SCHOLAR-1 in Patients with Refractory, Aggressive Non-Hodgkinlymphoma (NHL)あとで読む2017年12月19日 14:44
-
Acute Graft-Versus-Host Disease (GVHD)-Free Relapse-Free Survival (GRFS) and Chronic Gvhd (CRFS) in Alternative Donor Hematopoietic Cell Transplantation (HCT) in Adultsあとで読む2017年12月20日 12:32
-
The Presence of Pleural Effusion at Diagnosis Predicts Poor Outcomes in Diffuse Large B-Cell Lymphoma Patients with MYC-Rearrangement or Double Protein Expressionあとで読む2017年12月20日 12:33
-
Nicordの臍帯血移植への拡大：多施設第I/II相試験の最終報告
役に立った(3)Nicord Single Unit Expanded Umbilical Cord Blood Transplantation: Final Results of a Multicenter Phase I/II Trialあとで読む2017年12月21日 15:22
-
びまん性大細胞型B細胞リンパ腫の予後は腫瘍周囲微小環境によって予測される
役に立った(2)Lymphoma Microenvironment Signature Predicts Clinical Outcomes in Diffuse Large B-Cell Lymphoma Patientsあとで読む2017年12月21日 15:23
-
Prognostic Impact of Past History of Other Malignancies in Diffuse Large B Cell Lymphomaあとで読む2017年12月21日 15:23
-
Randomized phase II study of R-CHOP-14 versus R-CHOP-14 followed by CHASER as induction therapy for high-dose chemotherapy (HDT), LEED, and autologous stem-cell transplantation (ASCT) in poor-risk diffuse large B-cell lymphoma (DLBCL): Japan Clinical Oncology Group (JCOG) Study (JCOG0908)あとで読む2017年12月21日 15:23
-
The Prognostic Significance of the Complete IgH Rearrangement Pattern Using the BIOMED-2 Protocol in Diffuse Large B-Cell Lymphomaあとで読む2017年12月22日 15:19
-
Impact of the Double Expression of MYC and BCL2 on Outcomes of Primary Refractory Diffuse Large B-Cell Lymphoma Following R-CHOP Chemoimmunotherapyあとで読む2017年12月22日 15:22
-
Evaluation of Tumor Burden for Predicting Survival in Patients with Follicular Lymphoma Receiving First-Line R-CHOP Treatment: Comparison of Different Definition of GELF Criteriaあとで読む2017年12月22日 15:23
-
Maintenance Rituximab after First Line Treatment in Veterans with Follicular Lymphoma Is Associated with Prolonged Overall Survivalあとで読む2017年12月22日 17:19
